Why is xcopri a controlled substance

Overview

Xcopri (cenobamate) is an anticonvulsant medication developed by SK Life Science and approved by the U.S. Food and Drug Administration (FDA) on November 15, 2019, specifically for treating partial-onset seizures in adults with epilepsy. The Drug Enforcement Administration (DEA) subsequently classified it as a Schedule V controlled substance under the Controlled Substances Act, citing its potential for abuse and dependence, though with lower risk compared to higher-schedule drugs like opioids or benzodiazepines. This classification places Xcopri in a category with other medications such as pregabalin (Lyrica) and certain cough suppressants containing codeine, which have accepted medical uses but require regulatory oversight. The decision was based on preclinical data showing cenobamate's effects on the central nervous system, including sedation and euphoria at high doses, which could lead to misuse. Historically, anticonvulsants have faced scrutiny for off-label use and abuse potential, with Xcopri's scheduling reflecting ongoing efforts to balance therapeutic benefits with public health safety in epilepsy management.

How It Works

Xcopri works by modulating neuronal activity in the brain to reduce seizure frequency through multiple mechanisms, primarily by enhancing GABAergic inhibition and inhibiting voltage-gated sodium channels. Specifically, cenobamate acts as a positive allosteric modulator of GABA-A receptors, increasing the inhibitory effects of gamma-aminobutyric acid (GABA), the brain's main inhibitory neurotransmitter, which helps calm overexcited neurons that trigger seizures. Additionally, it blocks sodium channels on neurons, stabilizing their membranes and preventing the rapid firing of electrical signals that contribute to seizure propagation. This dual-action approach is unique among anticonvulsants and contributes to its efficacy in drug-resistant epilepsy cases. The medication is administered orally, typically starting at a low dose of 12.5 mg once daily and titrated up to a maintenance dose of 200 mg daily over weeks to minimize side effects like drowsiness. Metabolism occurs primarily in the liver via CYP2E1 and other enzymes, with a half-life of approximately 50-60 hours, allowing for once-daily dosing and steady-state concentrations that support seizure control.

Why It Matters

Xcopri's classification as a controlled substance matters because it impacts access, prescribing practices, and patient safety in epilepsy treatment, affecting an estimated 3.4 million Americans with epilepsy, of whom about 30-40% have drug-resistant forms. As a Schedule V drug, it requires stricter prescription monitoring, including potential state-level regulations like prescription drug monitoring programs (PDMPs), which help prevent diversion and misuse while ensuring appropriate use for seizure management. This regulatory framework balances the need for effective therapies—Xcopri has shown to reduce seizure frequency by up to 55.6% in clinical trials—with public health concerns about substance abuse, particularly in a population vulnerable to polypharmacy and comorbidities. The significance extends to healthcare costs and insurance coverage, as controlled substances may face additional scrutiny from payers, influencing treatment affordability and adherence. Overall, Xcopri's scheduling underscores the ongoing challenge in neurology to develop potent anticonvulsants that minimize abuse risks, ultimately aiming to improve quality of life for patients with refractory epilepsy while safeguarding against potential harms.